We are live on ! Find out more
MB

MPM BioImpact Portfolio holdings

AUM $1.64B
1-Year Est. Return 245.64%
This Fund
S&P 500
This Quarter Est. Return
+44.98%
1 Year Est. Return
+245.64%
3 Year Est. Return
+550.3%
5 Year Est. Return
+647.56%
10 Year Est. Return
–
AUM
$874M
AUM Growth
+$263M
Cap. Flow
+$99.1M
Cap. Flow %
11.34%
Top 10 Hldgs %
49.85%
Holding
55
New
15
Increased
6
Reduced
16
Closed
17

Top Buys

Rank Stock Value
1
QURE icon
uniQure
QURE
+$53.3M
2
AGIO icon
Agios Pharmaceuticals
AGIO
+$45.7M
3
LQDA icon
Liquidia Corp
LQDA
+$34.2M
4
CRVS icon
Corvus Pharmaceuticals
CRVS
+$21.6M
5
URGN icon
UroGen Pharma
URGN
+$17.5M

Top Sells

Rank Stock Value
1
RNAM
Avidity Biosciences
RNAM
+$33.1M
2
ZLAB icon
Zai Lab
ZLAB
+$25.3M
3
CMPX icon
Compass Therapeutics
CMPX
+$17.8M
4
ALKS icon
Alkermes
ALKS
+$16.5M
5
VERA icon
Vera Therapeutics
VERA
+$16.4M

Sector Composition

Rank Sector Weight
1 Healthcare 100%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
SPRY icon
51
ARS Pharmaceuticals
SPRY
$586M
– –
-1,303,399
Closed -$13.1M
VERA icon
52
Vera Therapeutics
VERA
$2.46B
– –
-563,075
Closed -$16.4M
WVE icon
53
Wave Life Sciences
WVE
$993M
– –
-1,505,262
Closed -$11M
ZLAB icon
54
Zai Lab
ZLAB
$2.93B
– –
-745,060
Closed -$25.3M
RAPP
55
Rapport Therapeutics
RAPP
$2.34B
– –
-71,807
Closed -$2.13M
1 2
3

Similar funds

OCM
Opti Capital Management New York $1.64B AUM 0% 1-Year Est. Return
LFS
Lutz Financial Services Omaha, Nebraska $1.64B AUM 15.04% 1-Year Est. Return
TIM
Triodos Investment Management Driebergen-Rijsenburg, Netherlands $1.64B AUM 37.98% 1-Year Est. Return
AAG
Armstrong Advisory Group Needham, Massachusetts $1.64B AUM 19.37% 1-Year Est. Return
MRG
Milestone Resources Group Road Town Tortola, British Virgin Islands $1.64B AUM 2.87% 1-Year Est. Return
EPW
Evolve Private Wealth Los Angeles, California $1.64B AUM
TWM
Tradition Wealth Management Edina, Minnesota $1.64B AUM 26.59% 1-Year Est. Return
MA
MONECO Advisors Fairfield, Connecticut $1.64B AUM 25.43% 1-Year Est. Return

MPM BioImpact's Q4 2025 Portfolio in Review

As of Q4 2025, MPM BioImpact held 55 positions worth $874M, up 43% from $611M the previous quarter. Its ten largest holdings account for 50% of the portfolio.

MPM BioImpact deployed $99.1M of net new capital in Q4 2025, opening 15 new positions and adding to 6 existing holdings. Its largest new stake was uniQure: 1,381,628 shares worth $33.1M.

By sector, the portfolio is most concentrated in Healthcare at 100% of assets, unchanged from a quarter earlier.

On the sell side, the largest reduction was Sarepta Therapeutics, an estimated $13.3M trimmed.

  • MPM BioImpact's largest Q4 2025 buy was uniQure: 1,381,628 shares worth $33.1M.
  • MPM BioImpact added most to Liquidia Corp in Q4 2025, an estimated $34.2M increase.
  • MPM BioImpact's biggest Q4 2025 reduction was Sarepta Therapeutics, cutting an estimated $13.3M.
  • MPM BioImpact fully exited Avidity Biosciences in Q4 2025, selling an estimated $33.1M.
  • MPM BioImpact's ten largest holdings make up 50% of its $874M portfolio in Q4 2025.
  • MPM BioImpact opened 15 new positions and closed 17 in Q4 2025.
  • MPM BioImpact's portfolio value rose 43% quarter-over-quarter to $874M.

Based on MPM BioImpact's 13F filing for Q4 2025, filed 17 Feb 2026.